A securities class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc., alleging the biopharmaceutical company made materially false and misleading statements regarding its investigational drug setrusumab (UX 143) for treating Osteogenesis Imperfecta. According to the litigation, Ultragenyx claimed the drug would increase bone density and reduce fracture rates, but the company allegedly failed to disclose that increased bone density does not necessarily translate to the promised reduction in fracture occurrences.
Investors who purchased Ultragenyx Pharmaceutical common stock between August 3, 2023 and December 26, 2025 may be eligible to participate in the class action. The lawsuit seeks to recover damages for shareholders who purchased securities during the alleged misrepresentation period. Legal counsel specializing in securities litigation advises eligible investors to act promptly to protect their rights.
The deadline to serve as lead plaintiff in the action is April 6, 2026. Investors considering participation in the litigation should consult with qualified securities attorneys to understand their eligibility and options before the deadline expires.